Education
About Us
Working with TipRanks
Follow Us
Bio-Path Holdings (BPTH)
OTHER OTC:BPTH
Top Page
Bio-Path Holdings
(OTC:BPTH)
37Underperform
Bio-Path Holdings (BPTH) vs. S&P 500 (SPY)
Market Cap
$1.66M
Dividend YieldN/A
Average Volume (3M)25.44K
Price to Earnings (P/E)―
Beta (1Y)-0.89
Revenue GrowthN/A
EPS Growth79.79%
CountryUS
Employees10
SectorHealthcare
Sector Strength43
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.40
Shares Outstanding8,307,892
10 Day Avg. Volume26,429
30 Day Avg. Volume25,441
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.50
Price to Sales (P/S)0.00
P/FCF Ratio-0.14
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit-54.06
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$9.00Price Target Upside4636.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bio-Path Holdings Business Overview & Revenue Model
Company DescriptionBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
How the Company Makes MoneyBio-Path Holdings makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model includes licensing agreements, partnerships with larger pharmaceutical firms, and potential future sales of approved drugs. Bio-Path may also receive milestone payments and royalties from these partnerships and collaborations as their drug candidates advance through clinical trials and, if successful, reach the market. Additionally, the company might engage in raising capital through stock offerings to fund its research and development efforts.
Bio-Path Holdings Financial Statement Overview
Summary
Bio-Path Holdings faces significant financial challenges with no revenue generation, persistent losses, and reliance on external financing. The high cash burn rate coupled with declining equity suggests substantial risks in maintaining operations without strategic shifts or new revenue streams.Income Statement
The company has not generated any revenue over the past years, which is a significant concern for sustainability. The net losses persist with no visible revenue growth, indicating potential financial instability.10
Very Negative
Balance Sheet
The company has a very low equity base with rising liabilities, leading to a deteriorating debt-to-equity ratio. The equity ratio has decreased significantly over the years, which suggests increased financial risk.20
Very Negative
Cash Flow
The operating cash flows are negative, reflecting a high burn rate without corresponding inflows from operations. Financing activities have been the primary source of cash, raising concerns about long-term viability without revenue generation.15
Very Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -32.00K | 0.00 | -178.00K | -178.00K | -161.00K | -151.00K | EBIT |
| -8.30M | 0.00 | -15.84M | -13.90M | -10.44M | -10.91M | EBITDA |
| -8.21M | 0.00 | -15.76M | -13.69M | -10.28M | -10.73M | Net Income Common Stockholders |
| -9.59M | -9.89M | -16.08M | -13.84M | -10.44M | -10.86M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 122.00K | 1.17M | 1.05M | 10.38M | 23.77M | 13.76M | Total Assets |
| 2.19M | 3.88M | 3.22M | 15.97M | 26.57M | 16.48M | Total Debt |
| 315.00K | 83.00K | 113.00K | 221.00K | 235.00K | 330.00K | Net Debt |
| 193.00K | -1.09M | -939.00K | -10.16M | -23.54M | -13.43M | Total Liabilities |
| 4.78M | 3.73M | 2.78M | 1.80M | 1.11M | 1.41M | Stockholders Equity |
| -2.59M | 154.00K | 441.00K | 14.17M | 25.46M | 15.07M |
| Cash Flow | Free Cash Flow | ||||
| -10.85M | -10.57M | -11.54M | -15.12M | -9.99M | -10.96M | Operating Cash Flow |
| -10.85M | -10.57M | -11.54M | -15.10M | -9.92M | -10.96M | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | -21.00K | -70.00K | 0.00 | Financing Cash Flow |
| 10.78M | 10.70M | 2.20M | 1.73M | 20.01M | 4.29M |
Bio-Path Holdings Technical Analysis
Neutral
0.19
Price Trends
0.16
Positive
0.42
Negative
0.72
Negative
Market Momentum
<0.01
Negative
55.74
Neutral
80.31
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTH, the sentiment is Neutral. The current price of 0.19 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.16, and below the 200-day MA of 0.72, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.74 is Neutral, neither overbought nor oversold. The STOCH value of 80.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BPTH.
Bio-Path Holdings Risk Analysis
Bio-Path Holdings disclosed 47 risk factors in its most recent earnings report. Bio-Path Holdings reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bio-Path Holdings Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $5.19B | 3.04 | -44.20% | 2.82% | 16.59% | -0.39% | |
51 Neutral | $3.54M | ― | ― | ― | ― | ||
39 Underperform | $2.92M | ― | -265.37% | ― | -13.05% | 49.76% | |
37 Underperform | $1.66M | ― | -3325.71% | ― | ― | 79.79% | |
37 Underperform | $4.78M | ― | -222.46% | ― | -7.74% | 93.25% | |
33 Underperform | $3.60M | ― | -233.77% | ― | ― | -97.16% | |
28 Underperform | $2.89M | ― | -120.01% | ― | ― | 97.84% |
* Healthcare Sector Average
Performance Comparison
BPTH
Bio-Path Holdings
0.19
-1.93
-91.04%
WINT
Windtree Therapeutics
0.82
-204.43
-99.60%
RSLS
ReShape Lifesciences
5.92
-253.20
-97.72%
UPC
Universe Pharmaceuticals
6.03
-1,487.97
-99.60%
ISPC
iSpecimen
1.18
-5.17
-81.42%
ONCO
Onconetix
0.09
-6.03
-98.53%
Bio-Path Holdings Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q3-2024)
| % Change Since: 5.56%|
Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment Positive
The call highlighted significant advancements in clinical trials and the expansion of the DNAbilize platform into new therapeutic areas, reflecting strong progress in drug development. Despite some financial challenges, such as increased administrative expenses and a decrease in cash position, the overall outlook remains positive due to substantial progress in pipeline advancements and research publications.Q3-2024 Updates
Positive Updates
Expansion of DNAbilize Platform
Initiation of clinical development program for BP-1001-A as a treatment for obesity and related metabolic diseases, marking the first non-cancer application of DNAbilize platform.
Progress in Cancer Treatment Trials
Continued advancement of Phase I/Ib clinical trials for BP1001-A in patients with solid tumors and BP1002 in refractory relapsed AML patients.
Publication and Potential of BP1003
Publication in Biomedicines journal highlighting the therapeutic potential of BP1003 in various cancer types, including breast, ovarian, and pancreatic cancer.
Financial Improvements
Net loss decreased to $2.1 million in Q3 2024 from $3.2 million in Q3 2023, with a decrease in research and development expenses.
Rapid Enrollment in Clinical Trials
Faster than projected enrollment for the third dosing cohort of 60 mg/m² in the BP1002 trial, completed within six weeks.
Negative Updates
Increased General and Administrative Expenses
General and administrative expenses increased to $1.3 million in Q3 2024 from $1.0 million in Q3 2023, primarily due to increased legal fees and salaries.
Cash Position Decrease
Cash decreased to $0.6 million as of September 30, 2024, from $1.1 million as of December 31, 2023.
Company Guidance
In the Bio-Path Holdings Q3 2024 earnings call, the company reported a net loss of $2.1 million, or $0.70 per share, which marks an improvement from the $3.2 million loss, or $6.36 per share, in the same period last year. Research and development expenses decreased to $1.3 million from $2.3 million, attributed to reduced manufacturing costs and clinical trial expenses. General and administrative expenses rose to $1.3 million from $1.0 million, driven by increased legal fees and salaries. The company's cash reserves stood at $0.6 million as of September 30, 2024, down from $1.1 million at the end of 2023, with $7.7 million net cash used in operating activities and $7.2 million generated from financing activities over the first nine months of 2024. Bio-Path is advancing its DNAbilize platform, aiming to expand into obesity and metabolic diseases while progressing clinical trials in oncology.Bio-Path Holdings Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
Bio-Path Holdings Reports Promising Pre-Clinical Results
Positive
Mar 19, 2025
On March 18, 2025, Bio-Path Holdings announced promising pre-clinical results for BP1001-A, indicating its potential as a treatment for obesity in Type 2 diabetes patients. The studies showed that BP1001-A attenuated fatty acid-induced insulin resistance and restored insulin sensitivity in muscle progenitor and skeletal muscle fiber cell models. This progress suggests a new application for BP1001-A beyond current weight loss drugs, potentially offering a novel therapeutic option for reducing glucose levels in patients with Type 2 diabetes. Bio-Path plans to advance these studies and file for regulatory designations to accelerate approval, with a final pre-clinical mouse model study expected in the first half of 2025 and an IND filing by year-end.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.